EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients

Jade M Kozuch iD, Carrie Burt, Kamyar Afshar iD, Saima Aslam iD, Gordon Yung, Mark Mariski, Eugene Golts, Ashley Feist

Transplant Infectious Disease · 2024-02 · 26 (1)

DOI: 10.1111/tid.14209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, online erschienen am 07.12.2023. Verfasst von Jade M Kozuch und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Immunosuppressive Agents, Azoles, Nitriles, Pyridines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The triazole antifungal isavuconazole (ISAVU) is used for prevention and treatment of fungal infections in solid organ transplant (SOT). SOT recipients commonly need to transition from one azole to another due to breakthrough infection, toxicity, or other reasons. The purpose of our study was to evaluate the effect of ISAVU on immunosuppressant concentrations in thoracic transplant recipients when ISAVU was started de novo or transitioned from another azole. We conducted a single‐center retrospective cohort study including 68 patients (51 lung, 14 heart, and 3 heart/lung transplant). Concentration to dosage ratios (C/D) of immunosuppressants were assessed at baseline, day 3, and weekly for 9 weeks. When starting ISAVU de novo, we observed a temporary doubling of tacrolimus exposure. Cyclosporine and sirolimus required dose decreases. Tacrolimus C/D increased by 110% at day 3 in patients started on ISAVU de novo then returned to baseline C/D ± 17% weeks 2‐9 (n = 8). One cyclosporine patient started on ISAVU de novo had variable C/D, and C/D increased by 219% ± 72% in 2 sirolimus patients. When transitioning from other azoles, tacrolimus and cyclosporine required about twice the initial dose. After week 1, tacrolimus C/D decreased by 53% ± 6% in patients transitioned from posaconazole (n = 33), voriconazole (n = 14), or fluconazole (n = 2). Cyclosporine C/D decreased by 45% ± 16% in patients transitioning from other azoles (posaconazole [n = 2], voriconazole [n = 2], fluconazole [n = 1]). Sirolimus C/D decreased by 73% ± 13% in patients transitioned from posaconazole (n = 7). Aside from the initial loading phase, ISAVU had a lesser degree of interaction with immunosuppressants than other azoles in loading phase, ISAVU had a lesser degree of interaction with immunosuppressants than other azoles in adjustments for the 4‐week period after initiating antifungal therapy with ISAVU or switching from another agent. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunosuppressive AgentsAzolesNitrilesPyridinesHumansAntifungal AgentsTacrolimusVoriconazoleFluconazoleTransplant RecipientsRetrospective StudiesTriazolesCyclosporineSirolimus

Stichwörter der Autor:innen

azole antifungalcalcineurin inhibitordrug interactionheart transplantisavuconazolelung transplanttherapeutic drug monitoring

Substanzen

Immunosuppressive AgentsisavuconazoleAzolesAntifungal AgentsTacrolimusVoriconazoleFluconazoleTriazolesCyclosporineSirolimus

Autor:innen und Institutionen

  • Department of Pharmacy, University of California San Diego, La Jolla, California, USA.
  • Department of Pharmacy, Scripps Memorial Hospital, La Jolla, California, USA.
  • Division of Pulmonary and Critical Care, University of California San Diego, La Jolla, California, USA.
  • Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
  • Division of Cardiothoracic Surgery, University of California San Diego, La Jolla, California, USA.
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Jade M Kozuch, Kamyar Afshar, Saima Aslam

Zitieren

APA

Kozuch, J. M., Burt, C., Afshar, K., Aslam, S., Yung, G., Mariski, M., Golts, E., & Feist, A. (2024). Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients. Transplant Infectious Disease, 26(1). https://doi.org/10.1111/tid.14209

Vancouver

Kozuch JM, Burt C, Afshar K, Aslam S, Yung G, Mariski M, et al. Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients. Transplant Infectious Disease. 2024;26(1). doi:10.1111/tid.14209

BibTeX
@article{Kozuch2024,
  author = {Kozuch, Jade M and Burt, Carrie and Afshar, Kamyar and Aslam, Saima and Yung, Gordon and Mariski, Mark and Golts, Eugene and Feist, Ashley},
  title = {Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients},
  journal = {Transplant Infectious Disease},
  year = {2024},
  volume = {26},
  number = {1},
  doi = {10.1111/tid.14209}
}
Kostenlos starten →